midazolam has been researched along with fedratinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krishna, G; LoRusso, PM; Ogasawara, K; Olszanski, AJ; Palmisano, M; Rixe, O; Xu, C; Yin, J | 1 |
| Krishna, G; Surapaneni, S; Wu, F | 1 |
1 trial(s) available for midazolam and fedratinib
| Article | Year |
|---|---|
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Male; Metoprolol; Midazolam; Middle Aged; Neoplasms; Omeprazole; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |
1 other study(ies) available for midazolam and fedratinib
| Article | Year |
|---|---|
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Topics: Area Under Curve; Computer Simulation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Labeling; Healthy Volunteers; Humans; Janus Kinase 2; Ketoconazole; Midazolam; Models, Biological; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrrolidines; Sulfonamides | 2020 |